icer white paper affordable access to glp-1 obesity medications 2025 Big policy shift in medicine. Starting July 1, 2026, Medicare will launch a temporary “GLP-1 Bridge” program allowing eligible patients drugs like Zepbound and Wegovy for about $50/month. For Prevalence of use and interest

If a GLP-1 medication is stopped, those conditions should be reassessed, since weight regain can increase medication requirements, he says

10.1007/s00204-024-03879-z 104 SieberP.SchferA.LieberherrR.CaimiS

References Madigan, M

Tell all your healthcare providers that you are taking Zepbound before you are scheduled to have surgery or other procedures

Our meals are different

Compounded drugs can be important for overcoming shortages or meeting unique patient needsbut compounders should not try to compound drugs in a way that circumvents FDAs approval process. The FDA claims the companies are mass marketing their GLP-1s as similar alternatives to FDA-approved drugs